News|Videos|October 22, 2025

Ashland Previews Fall Conference Exhibits, Including Expanded High-Purity Sugar Portfolio: Video Summary

At CPHI and AAPS, Ashland plans to detail the impacts of its advanced excipients: ultra-low nitrite materials curb nitrosamine risk, while high-purity sucrose stabilizes complex biologics.

Ashland is enhancing its pharmaceutical ingredients portfolio, focusing on high-purity excipients for injectables and low-nitrite offerings for oral solid doses, according to an announcement detailing products to be featured at CPHI Frankfurt, from Oct. 28–30, 2025, and AAPS PharmSci 360, to be held in San Antonio, Texas from Nov. 9 to 12, 2025 (1).